thiazolidinediones

Summary

Summary: THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).

Top Publications

  1. pmc Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
    Arun J Sanyal
    Virginia Commonwealth University, Richmond, USA
    N Engl J Med 362:1675-85. 2010
  2. ncbi Fat and beyond: the diverse biology of PPARgamma
    Peter Tontonoz
    Howard Hughes Medical Institute and Department of Pathology and Laboratory Medicine, University of California Los Angeles, CA 90095, USA
    Annu Rev Biochem 77:289-312. 2008
  3. pmc Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study
    James D Lewis
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Diabetes Care 34:916-22. 2011
  4. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
  5. ncbi Thiazolidinediones and PPARγ agonists: time for a reassessment
    Bertrand Cariou
    Unité Mixte de Recherche 1087, Institut National de la Sante et de la Recherche Medicale INSERM, Nantes 44000, France
    Trends Endocrinol Metab 23:205-15. 2012
  6. ncbi PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
    N Maeda
    Department of Internal Medicine and Molecular Science (B5, Graduate School of Medicine, Osaka University, Osaka, Japan
    Diabetes 50:2094-9. 2001
  7. ncbi Thiazolidinediones
    Hannele Yki-Jarvinen
    Division of Diabetes, Department of Medicine, University of Helsinki, Finland
    N Engl J Med 351:1106-18. 2004
  8. pmc Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5
    Jang Hyun Choi
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 466:451-6. 2010
  9. ncbi Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:2457-71. 2007
  10. pmc Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones
    Paul A Dutchak
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9041, USA
    Cell 148:556-67. 2012

Detail Information

Publications385 found, 100 shown here

  1. pmc Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
    Arun J Sanyal
    Virginia Commonwealth University, Richmond, USA
    N Engl J Med 362:1675-85. 2010
    ..Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease...
  2. ncbi Fat and beyond: the diverse biology of PPARgamma
    Peter Tontonoz
    Howard Hughes Medical Institute and Department of Pathology and Laboratory Medicine, University of California Los Angeles, CA 90095, USA
    Annu Rev Biochem 77:289-312. 2008
    ..Here, we review recent advances in our understanding of the diverse biological actions of PPARgamma with an eye toward the expanding therapeutic potential of PPARgamma agonist drugs...
  3. pmc Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study
    James D Lewis
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Diabetes Care 34:916-22. 2011
    ..This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes...
  4. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  5. ncbi Thiazolidinediones and PPARγ agonists: time for a reassessment
    Bertrand Cariou
    Unité Mixte de Recherche 1087, Institut National de la Sante et de la Recherche Medicale INSERM, Nantes 44000, France
    Trends Endocrinol Metab 23:205-15. 2012
    b>Thiazolidinediones (TZDs) are anti-diabetic drugs that act as insulin sensitizers and are used in the management of type 2 diabetes mellitus...
  6. ncbi PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
    N Maeda
    Department of Internal Medicine and Molecular Science (B5, Graduate School of Medicine, Osaka University, Osaka, Japan
    Diabetes 50:2094-9. 2001
    ..In this study, we demonstrate the inducing effects of thiazolidinediones (TZDs), which are synthetic PPARgamma ligands, on the expression and secretion of adiponectin in humans and ..
  7. ncbi Thiazolidinediones
    Hannele Yki-Jarvinen
    Division of Diabetes, Department of Medicine, University of Helsinki, Finland
    N Engl J Med 351:1106-18. 2004
  8. pmc Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5
    Jang Hyun Choi
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 466:451-6. 2010
    ....
  9. ncbi Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:2457-71. 2007
    ..Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined...
  10. pmc Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones
    Paul A Dutchak
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9041, USA
    Cell 148:556-67. 2012
    ..Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ...
  11. pmc Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
    Haiyan Xu
    Millennium Pharmaceuticals, Cambridge, Massachusetts, USA
    J Clin Invest 112:1821-30. 2003
    ..We propose that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue...
  12. ncbi Diabetes and cancer: a consensus report
    Edward Giovannucci
    Departments of Nutrition and Epidemiology, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    CA Cancer J Clin 60:207-21. 2010
    ..In addition, key unanswered questions for future research are posed...
  13. ncbi Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    Steven E Kahn
    Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle 98108, USA
    N Engl J Med 355:2427-43. 2006
    The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.
  14. ncbi Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Lancet 376:431-9. 2010
    ....
  15. ncbi Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arch Intern Med 170:1191-1201. 2010
    ..Controversy regarding the effects of rosiglitazone therapy on myocardial infarction (MI) and cardiovascular (CV) mortality persists 3 years after a meta-analysis initially raised concerns about the use of this drug...
  16. pmc Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
    Isabelle N Colmers
    Department of Public Health Sciences, University of Alberta, Edmonton, Alta
    CMAJ 184:E675-83. 2012
    Patients with type 2 diabetes have a 40% increased risk of bladder cancer. Thiazolidinediones, especially pioglitazone, may increase the risk...
  17. ncbi The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways
    Lee G D Fryer
    Cellular Stress Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom
    J Biol Chem 277:25226-32. 2002
    ..This finding raises the possibility that a number of the beneficial effects of the thiazolidinediones could be mediated via activation of AMPK...
  18. ncbi Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
    Barbara Brunmair
    Department of Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Vienna, Austria
    Diabetes 53:1052-9. 2004
    Metformin and thiazolidinediones (TZDs) are believed to exert their antidiabetic effects via different mechanisms...
  19. pmc Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
    Jang Hyun Choi
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 477:477-81. 2011
    ..Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ...
  20. pmc Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
    Ajit S Divakaruni
    Department of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 110:5422-7. 2013
    ..We report that clinically relevant concentrations of thiazolidinediones (TZDs), a widely used class of insulin sensitizers, acutely and specifically inhibit mitochondrial pyruvate ..
  21. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  22. ncbi PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
    P Tontonoz
    The Salk Institute for Biological Studies, La Jolla, California 92037, USA
    Cell 93:241-52. 1998
    ..These results reveal a novel signaling pathway controlling differentiation and lipid metabolism in monocytic cells, and suggest that endogenous PPARgamma ligands may be important regulators of gene expression during atherogenesis...
  23. pmc Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study
    Ronac Mamtani
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Natl Cancer Inst 104:1411-21. 2012
    ..In this study, we assessed the risk of bladder cancer associated with the use of TZDs and between pioglitazone and rosiglitazone, an alternative TZD...
  24. pmc Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients
    X X He
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 22:2640-5. 2011
    ..This study examined the impact of these drugs on the outcomes of diabetic patients with prostate cancer to provide a basis for diabetes management strategy in these patients...
  25. pmc PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein
    Haruya Ohno
    UCSF Diabetes Center and Department of Cell and Tissue Biology, University of California, San Francisco, 35 Medical Center Way, San Francisco, CA 94143 0669, USA
    Cell Metab 15:395-404. 2012
    ..Identifying compounds that stabilize PRDM16 protein may represent a plausible therapeutic pathway for the treatment of obesity and diabetes...
  26. pmc Pioglitazone and bladder cancer: a population-based study of Taiwanese
    Chin Hsiao Tseng
    Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
    Diabetes Care 35:278-80. 2012
    ..The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association...
  27. ncbi Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, UK
    Lancet 373:2125-35. 2009
    ..We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety...
  28. pmc Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
    Yoon K Loke
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    CMAJ 180:32-9. 2009
    ..Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density...
  29. pmc Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model
    Rachel E Nisbet
    Department of Medicine, Atlanta Veterans Affairs and Emory University Medical Centers, Atlanta, Georgia 30033, USA
    Am J Respir Cell Mol Biol 42:482-90. 2010
    ....
  30. ncbi Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice
    Michael T Heneka
    Department of Neurology, University of Bonn, Bonn, Germany
    Brain 128:1442-53. 2005
    ..These findings demonstrate that anti-inflammatory drugs can act rapidly to inhibit inflammatory responses in the brain and negatively modulate amyloidogenesis...
  31. ncbi Pioglitazone for diabetes prevention in impaired glucose tolerance
    Ralph A DeFronzo
    Texas Diabetes Institute and University of Texas Health Science Center, San Antonio, TX 78229, USA
    N Engl J Med 364:1104-15. 2011
    ..Impaired glucose tolerance is associated with increased rates of cardiovascular disease and conversion to type 2 diabetes mellitus. Interventions that may prevent or delay such occurrences are of great clinical importance...
  32. ncbi Reactive oxygen species have a causal role in multiple forms of insulin resistance
    Nicholas Houstis
    Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02141, USA
    Nature 440:944-8. 2006
    ..Together, our findings suggest that increased ROS levels are an important trigger for insulin resistance in numerous settings...
  33. ncbi Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization
    Terry P Combs
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Endocrinology 143:998-1007. 2002
    ..Furthermore, Acrp30 is likely to be a biomarker of in vivo PPARgamma activation...
  34. pmc Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
    Yoon Kong Loke
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK
    BMJ 342:d1309. 2011
    To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes.
  35. pmc Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone
    Leanne Wilson-Fritch
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, 01601, USA
    J Clin Invest 114:1281-9. 2004
    ....
  36. ncbi Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
    Chia Hsuin Chang
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Hepatology 55:1462-72. 2012
    ..case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs)...
  37. ncbi Beta-cell preservation with thiazolidinediones
    Ian W Campbell
    Victoria Hospital, Kirkcaldy, Fife, Scotland
    Diabetes Res Clin Pract 76:163-76. 2007
    ..Clinical study evidence from several sources now suggests that thiazolidinediones (TZDs) have profound effects on the beta-cell, such as improving insulin secretory capacity, preserving beta-..
  38. pmc Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastroenterology 134:688-95. 2008
    ..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)...
  39. ncbi A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
    J Liutkus
    Medicine Professional Corporation, Cambridge, Ontario, Canada
    Diabetes Obes Metab 12:1058-65. 2010
    To test the hypothesis that glycaemic control with exenatide added to thiazolidinediones (TZDs) with or without metformin was superior to placebo.
  40. ncbi Anti-apoptotic actions of PPAR-gamma against ischemic stroke
    Wen Hsuan Fong
    Neuroscience Division, Institute of Biomedical Sciences, Academia Sinica, Rm 404, Taipei, Taiwan, Republic of China
    Mol Neurobiol 41:180-6. 2010
    ..This review further supports the notion that PPAR-gamma may serve as a potential therapeutic target for treating ischemic stroke...
  41. ncbi Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
    Montserrat Camps
    Serono Pharmaceutical Research Institute, Serono International S A, 14, Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Nat Med 11:936-43. 2005
    ..Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis...
  42. ncbi Rosiglitazone induces mitochondrial biogenesis in mouse brain
    Jay C Strum
    Department of Quantitative Expression, Division of Genetics Research, GlaxoSmithKline, Research Triangle Park, NC 27278, USA
    J Alzheimers Dis 11:45-51. 2007
    ....
  43. pmc Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones
    Min Lu
    Department of Medicine, University of California San Diego UCSD, San Diego, California, USA
    Nat Med 17:618-22. 2011
    ..is a determinant of insulin sensitivity and this receptor mediates the insulin-sensitizing effects of thiazolidinediones (TZDs)...
  44. ncbi Epidemiological aspects of neoplasms in diabetes
    Antonio Nicolucci
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030, S Maria Imbaro Ch, Italy
    Acta Diabetol 47:87-95. 2010
    ..The prevalence of diabetes and obesity is rapidly increasing worldwide; if these conditions are associated even with a small increase in the risk of cancer, this will translate into important consequences for public health...
  45. ncbi Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis
    Karen Fuenzalida
    Centro de Regulación Celular y Patologia Joaquín V Luco and Millennium Institute for Fundamental and Applied Biology, Department of Cellular and Molecular Biology, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile
    J Biol Chem 282:37006-15. 2007
    ..Altogether, these data suggest that PPARgamma supports survival in neurons in part through a mechanism involving increased expression of Bcl-2...
  46. ncbi Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo
    Jun Yu
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia
    Hepatology 43:134-43. 2006
    ..PPARgamma therefore represents a putative molecular target for chemopreventive therapy or inhibition of liver cancer growth...
  47. ncbi Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment
    Liam R Brunham
    Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada
    Nat Med 13:340-7. 2007
    ..These experiments establish a new role for Abca1 in beta-cell cholesterol homeostasis and insulin secretion, and suggest that cholesterol accumulation may contribute to beta-cell dysfunction in type 2 diabetes...
  48. ncbi Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
    R T Nolte
    Department of Structural Chemistry, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA
    Nature 395:137-43. 1998
    ....
  49. ncbi Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone
    Kwame Osei
    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA
    Metabolism 56:24-9. 2007
    ..However, the effects of thiazolidinediones (TZDs) on HIE remain uncertain...
  50. pmc Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione
    Zhouji Chen
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 287:23537-48. 2012
    Currently approved thiazolidinediones (TZDs) are effective insulin-sensitizing drugs that may have efficacy for treatment of a variety of metabolic and inflammatory diseases, but their use is limited by side effects that are mediated ..
  51. pmc Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
    E Boettcher
    Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA 92093, USA
    Aliment Pharmacol Ther 35:66-75. 2012
    b>Thiazolidinediones (TZDs) have been used in the treatment of non-alcoholic steatohepatitis (NASH)...
  52. ncbi Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database
    Domenico Motola
    Department of Pharmacology, University of Bologna, Bologna, Italy
    Drug Saf 35:315-23. 2012
    The risk of myocardial infarction, macular oedema and bone fractures associated with thiazolidinediones (TZDs) has been extensively investigated.
  53. pmc Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue
    Thomas Cadoudal
    Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche S 747, Universite Paris Descartes, Centre Universitaire des Saints Peres, Paris, France
    Diabetes 57:2272-9. 2008
    ..pyruvate, as glyceroneogenesis, a pathway controlling fatty acid release from white adipose tissue (WAT). Thiazolidinediones activate glyceroneogenesis...
  54. ncbi Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer
    Mahmoud Mansour
    Department of Anatomy, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
    Int J Oncol 38:537-46. 2011
    ..b>Thiazolidinediones (TZDs), a family of PPARγ activators and type 2 anti-diabetic drugs, exhibit anti-tumor apoptotic effects ..
  55. pmc A role for central nervous system PPAR-γ in the regulation of energy balance
    Karen K Ryan
    Department of Internal Medicine, Division of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Nat Med 17:623-6. 2011
    ..These findings have implications for the widespread clinical use of TZD drugs and for understanding the etiology of diet-induced obesity...
  56. ncbi Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive
    John Dormandy
    Department of Clinical Vascular Research, St George s Hospital, London, UK
    Drug Saf 32:187-202. 2009
    ..These results suggest that any beneficial effects of pioglitazone on macrovascular outcomes are accompanied by good long-term tolerability in this population of very high-risk patients with type 2 diabetes and established CVD...
  57. pmc Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease
    Rodrigo A Quintanilla
    Department of Anesthesiology, University of Rochester, University Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Biol Chem 283:25628-37. 2008
    ....
  58. ncbi Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects
    Gautam K Bandyopadhyay
    Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, 9500 Gilman Dr, La Jolla, 92093, USA
    Diabetes 55:2277-85. 2006
    ....
  59. ncbi Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor
    Markus C Stühlinger
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Falk Cardiovascular Research Center, 300 Pasteur Dr, Stanford, CA 94305, USA
    JAMA 287:1420-6. 2002
    ..Several cardiovascular risk factors are associated with reduced sensitivity to insulin, but elevated ADMA concentrations have not been fully linked to the metabolic syndrome...
  60. pmc Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle
    Weimin He
    Departments of Medicine and Biology, University of California at San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 100:15712-7. 2003
    ..insulin resistance (IR), dyslipidemia, and other metabolic abnormalities, is responsive to antidiabetic thiazolidinediones (TZDs)...
  61. pmc Cohort study of pioglitazone and cancer incidence in patients with diabetes
    Assiamira Ferrara
    Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
    Diabetes Care 34:923-9. 2011
    ....
  62. ncbi Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist
    Nektaria Nicolakakis
    Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    J Neurosci 28:9287-96. 2008
    ....
  63. ncbi 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
    B M Forman
    Salk Institute for Biological Studies, La Jolla, California 92037, USA
    Cell 83:803-12. 1995
    ..Thus, adipogenic prostanoids and antidiabetic thiazolidinediones initiate key transcriptional events through a common nuclear receptor signaling pathway...
  64. ncbi Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists
    Mei Nie
    Division of Respiratory Medicine, City Hospital, University of Nottingham, Nottingham NG5 1PB, United Kingdom
    J Biol Chem 280:2550-61. 2005
    ..The interaction may have wide applications and may provide a potential target for pharmacological and molecular intervention...
  65. ncbi Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model
    Kohei Honda
    Inserm U547 IFR17, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
    J Allergy Clin Immunol 113:882-8. 2004
    ..Recently, PPAR-gamma has been shown to play an important role in the control of inflammatory responses, including within the lung, acting on both immune and nonimmune cells...
  66. pmc Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer
    X He
    Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:1771-80. 2012
    ....
  67. ncbi Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe
    Jerry R Colca
    Pharmacia Corporation, Kalamazoo, Michigan 49001, USA
    Am J Physiol Endocrinol Metab 286:E252-60. 2004
    b>Thiazolidinediones address underlying causes of type 2 diabetes, although their mechanism of action is not clearly understood...
  68. ncbi Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
    Tomohiko Sato
    Department of Geriatric Medicine, Tokyo Medical University, 6 7 1 Nishishinjuku Shinjuku ku, Tokyo 160 0023, Japan
    Neurobiol Aging 32:1626-33. 2011
    ..Pioglitazone may offer a novel strategy for the treatment of AD...
  69. ncbi Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress
    Hitoshi Ishida
    Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
    Metabolism 53:488-94. 2004
    ..Treatment with pioglitazone thus protects against beta-cell damage and would be useful for restoration of insulin secretory capacity in obese diabetes individuals...
  70. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes...
  71. ncbi Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
    Carol Koro
    GlaxoSmithKline, Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, USA
    Pharmacoepidemiol Drug Saf 16:485-92. 2007
    We conducted three nested case-control studies to evaluate the risk of breast, colon, and prostate cancers developing in patients exposed to thiazolidinediones (TZDs) compared with other anti-diabetic agents.
  72. ncbi Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation
    Sakiko Ohga
    Dept of Medicine and Clinical Science, Okayama Univ Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Am J Physiol Renal Physiol 292:F1141-50. 2007
    ..Our results suggest that the preventive effects of pioglitazone may be mediated by its anti-inflammatory actions, including inhibition of NF-kappaB activation, ICAM-1 expression, and macrophage infiltration in the diabetic kidney...
  73. ncbi Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats
    Seung Won Park
    Department of Neurological Surgery, University of Wisconsin, Madison, WI 53792, USA
    J Pharmacol Exp Ther 320:1002-12. 2007
    b>Thiazolidinediones (TZDs) are potent synthetic agonists of the ligand-activated transcription factor peroxisome proliferator-activated receptor-gamma (PPARgamma)...
  74. ncbi Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model
    Luis Escribano
    Division of Neurosciences, CIMA, University of Navarra, Av Pio XII 55, 31008 Pamplona, CIBERNED, Spain
    Biochem Biophys Res Commun 379:406-10. 2009
    ..In parallel with behavioural studies, rosiglitazone also normalized GR levels in older animals. This effect may contribute to explain the attenuation of memory decline by PPARgamma activation in an AD mouse model...
  75. pmc Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus
    Zeina A Habib
    Center for Health Services Research, Henry Ford Health System, 1 Ford Place, 3A Center for Health Services Research, Detroit, Michigan 48202, USA
    J Clin Endocrinol Metab 95:592-600. 2010
    ..Thiazolidinedione (TZD) use has recently been associated with an increased risk of fractures...
  76. ncbi Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    David J Graham
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 4314, Silver Spring, MD 20993 0002, USA
    JAMA 304:411-8. 2010
    ..Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes...
  77. ncbi Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel
    Hidemi Nomura
    Department of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Aomori, Japan
    J Pharmacol Sci 108:258-65. 2008
    ..While endothelium-dependent relaxation is mediated via nitric oxide, the endothelium-independent one is responsible for smooth muscle K+ (K(V), K(IR))-channel opening...
  78. pmc PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice
    Takeshi Kanda
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Invest 119:110-24. 2009
    ....
  79. ncbi The nuclear hormone receptor PPARγ as a therapeutic target in major diseases
    Martina Victoria Schmidt
    Institute of Biochemistry I Pathobiochemistry, Faculty of Medicine, Goethe University Frankfurt, Germany
    ScientificWorldJournal 10:2181-97. 2010
    ..Thus, synthetic PPARγ agonists, the thiazolidinediones (TZDs), are used in type 2 diabetes therapy as insulin sensitizers...
  80. ncbi Essential role of mitochondrial function in adiponectin synthesis in adipocytes
    Eun Hee Koh
    Department of Internal Medicine, University of Ulsan College of Medicine, Poongnap dong, Songpa Ku, Seoul 138 736, Korea
    Diabetes 56:2973-81. 2007
    ..This study was undertaken to test the hypothesis that mitochondrial function is linked to adiponectin synthesis in adipocytes...
  81. pmc The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
    Adam B Mayerson
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8020, USA
    Diabetes 51:797-802. 2002
    ..04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in ..
  82. ncbi Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis
    Christian Werner
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, 66421 Homburg, Saar, Germany
    Atherosclerosis 216:23-34. 2011
    ..PPAR-γ agonists may mediate vascular effects in addition to insulin sensitizing. We therefore examined whether pioglitazone regulates vascular telomere biology...
  83. ncbi Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities
    S Meidute Abaraviciene
    Department of Clinical Science, Division of Endocrine Pharmacology, UMAS, CRC, 205 02, Malmo, Sweden
    Cell Mol Life Sci 65:2256-65. 2008
    ..We suggest that ROZ counteracts palmitateinduced deleterious effects on beta-cell function via suppression of iNOS, pro-apoptotic MAPKs and caspase-3 activities, as evidenced by restoration of glucose-stimulated insulin release...
  84. ncbi INT131: a selective modulator of PPAR gamma
    Alykhan Motani
    Amgen, Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    J Mol Biol 386:1301-11. 2009
    ..To overcome the well-known shortcomings of thiazolidinediones, we have identified INT131 (formerly T131 and AMG131) as a potent selective ligand for PPAR gamma that is ..
  85. ncbi Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway
    Wei Zhang
    Departments of Gastroenterology and Hepatology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Clin Exp Pharmacol Physiol 39:1026-33. 2012
    b>Thiazolidinediones (TZDs) markedly reduce hepatic steatosis in both rodents and humans. However, the effects and mechanisms of action of TZDs on hepatic fibrosis remain unclear...
  86. ncbi In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone
    T L Yue Tl
    Department of Cardiovascular Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
    Circulation 104:2588-94. 2001
    ..CONCLUSIONS: ROSI reduced myocardial infarction and improved contractile dysfunction caused by ischemia/reperfusion injury. The cardioprotective effect of ROSI was most likely due to inhibition of the inflammatory response...
  87. ncbi Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
    Brent A Neuschwander-Tetri
    University Liver Center, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    Hepatology 38:1008-17. 2003
    ....
  88. ncbi Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis
    B Gustafson
    The Lundberg Laboratory for Diabetes Research, Center of Excellence for Metabolic and Cardiovascular Research, Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Blå Stråket 3, 413 45 Gothenburg, Sweden
    Diabetologia 53:536-40. 2010
    ..Previous studies have shown that treatment of type 2 diabetic patients with thiazolidinediones (TZDs) reduces bone density and increases risk of bone fractures, while body fat is increased.
  89. ncbi Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma
    Ming Chang Chiang
    Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan
    Hum Mol Genet 19:4043-58. 2010
    ..We demonstrated that the systematic downregulation of PPARγ seems to play a critical role in the dysregulation of energy homeostasis observed in HD, and that PPARγ is a potential therapeutic target for this disease...
  90. pmc Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance
    Naoki Kobayashi
    Department of Metabolic Diseases, Graduate School of Medicine, and Translational Systems Biology and Medicine Initiative, University of Tokyo, Tokyo 113 0033, Japan
    Proc Natl Acad Sci U S A 108:5753-8. 2011
    ..These data suggest that PI3Kγ plays a crucial role in the development of both obesity-induced inflammation and systemic insulin resistance and that PI3Kγ can be a therapeutic target for type 2 diabetes...
  91. pmc Repression of beta-catenin signaling by PPAR gamma ligands
    Desheng Lu
    University of California San Diego UCSD Moores Cancer Center, La Jolla, CA 92093, USA
    Eur J Pharmacol 636:198-202. 2010
    ....
  92. ncbi PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations
    Aamer Abbas
    Department of Internal Medicine, Texas Tech University, El Paso, Texas 79905, USA
    Cardiovasc Hematol Agents Med Chem 10:124-34. 2012
    ..PPARγ has high expression in fat, low expression in the liver, and very low expression in the muscle. The thiazolidinediones (TZD) are synthetic ligands of PPARγ...
  93. pmc Complement factor H is expressed in adipose tissue in association with insulin resistance
    José María Moreno-Navarrete
    Department of Diabetes, Endocrinology and Nutrition, Institut d Investigació Biomédica de Girona, and CIBER Fisiopatologia Obesidad y Nutricion, Instituto de Salud Carlos III, Girona, Spain
    Diabetes 59:200-9. 2010
    ..Our objective was to study the associations between circulating and adipose tissue gene expressions of CFH and complement factor B (fB; CFB) with obesity and insulin resistance...
  94. ncbi Polycystic ovary syndrome
    David A Ehrmann
    University of Chicago, Department of Medicine, Section of Endocrinology, Chicago, USA
    N Engl J Med 352:1223-36. 2005
  95. ncbi A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc L MARC, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Diab Vasc Dis Res 4:181-93. 2007
    ..In summary, tesaglitazar provided similar glycaemic control to pioglitazone, was associated with significant improvement in lipid and lipoprotein variables, and increased serum creatinine in a dose-dependent manner...
  96. ncbi Insulin resistance and the endothelium
    Willa A Hsueh
    Division of Endocrinology, Diabetes, and Hypertension, University of California, Los Angeles, USA
    Am J Med 117:109-17. 2004
    ..This article reviews the relation between endothelial dysfunction and cardiovascular disease, assesses the endothelium in the spectrum of insulin resistance, and examines the effect of the thiazolidinediones on endothelial function.
  97. ncbi A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Renata Belfort
    University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    N Engl J Med 355:2297-307. 2006
    ..Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus...
  98. ncbi Managing type 2 diabetes: going beyond glycemic control
    Mark W Stolar
    Northwestern University Medical School, Chicago, IL 60611, USA markstolar nwinternist com
    J Manag Care Pharm 14:s2-19. 2008
    ..Attainment of treatment goals is associated with a decreased risk of diabetes-related complications, costs, and health care utilization...
  99. ncbi Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice
    Takahiro Akahori
    Department of Surgery, Nara Medical University, Nara, Japan
    J Hepatol 47:784-92. 2007
    ..However, the precise role of PPARgamma in acute liver injury remains unknown...
  100. ncbi Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry
    Thomas Mendgen
    Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Im Neuenheimer Feld 364, D 69120 Heidelberg, Germany
    J Med Chem 55:743-53. 2012
    ..An amount of 163 rhodanines, hydantoins, thiohydantoins, and thiazolidinediones were synthesized and tested against several targets...
  101. ncbi Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation
    Xueping Liu
    Department of Senile Neurology, Provincial Hospital affiliated to Shandong University, Jinan, Shandong 250021, PR China
    Eur J Pharmacol 629:153-8. 2010
    ....

Research Grants68

  1. Mitochondrial Protection Within Chronically Ischemic Myocardium
    Edward O McFalls; Fiscal Year: 2010
    ..Using this model, we propose that a class of drugs used in diabetic patients that has been associated with heart failure exacerbations, alters the mitochondrial energy production in a similar way. ..
  2. Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
    RONALD JAY KOENIG; Fiscal Year: 2013
    ..In Specific Aim 3, the effects of PPARg ligands (thiazolidinediones) on xenograft tumor and metastasis formation will be evaluated in NOD-SCID mice...
  3. Transcriptional Regulation of Natriuetic Sensitivity in Diabetes Mellitus
    PATIENCE O OBIH; Fiscal Year: 2012
    ..The thiazolidinediones (TZDs) have been introduced for the treatment of type 2 diabetes...
  4. Novel PPAR-Independent Peroxisome Proliferators for Type 2 Diabetes
    LIDIA NIEROBISZ; Fiscal Year: 2011
    ..We propose to develop novel PPAR-Independent Peroxisome Proliferators for Type 2 Diabetes to address this market need. ..
  5. Synergistic Roles of Adiponectin & PPARgamma in Beta-Cell Survival/Proliferation
    William L Holland; Fiscal Year: 2010
    ..b>Thiazolidinediones (TZDs) are a novel class of oral antidiabetic agents which improves insulin sensitivity through activation ..
  6. Nitrated fatty acids/PPARgamma in the control of renal and vascular functions
    Tianxin Yang; Fiscal Year: 2012
    ..function of PPAR in the distal nephron that underlies fluid retention and body weight gains associated with thiazolidinediones (TZDs)...
  7. The Role of PPAR Gamma in Fat-Resident Regulatory T Cells and Glucose Homeostasis
    SAGAR PRADEEP BAPAT; Fiscal Year: 2013
    ..Furthermore, the necessity of PPAR!"in fTregs for the therapeutic mechanism of action of thiazolidinediones (TZDs), an important anti-diabetic class of drugs that are PPAR!"agonists, will be investigated using a ..
  8. A novel axis regulates adipocyte plasticity
    Sean Hartig; Fiscal Year: 2013
    ..Therapeutic PPAR? activation by thiazolidinediones increases insulin sensitivity and fat storage efficiency in T2DM with serious, negative side effects ..
  9. Connection of Mineral and Energy Metabolism by the Nuclear Receptor PPAR-gamma
    Yihong Wan; Fiscal Year: 2013
    ..Synthetic PPAR3 ligands thiazolidinediones (TZDs) are FDA-approved drugs for insulin resistance and type 2 diabetes...
  10. Virtual Screening Development to Complement Experimental Screening for PPAR Modul
    Stephanie N Lewis; Fiscal Year: 2012
    ..b>Thiazolidinediones (TZDs) work by targeting peroxisome proliferator-activated receptor-gamma (PPAR(), which is a protein known ..
  11. Modulation of PPAR-gamma phosphorylation at S273 regulates insulin sensitivity
    ALEXANDER BANKS; Fiscal Year: 2013
    ..by applicant): PPAR-gamma is the target of highly effective but controversial diabetes medications, the thiazolidinediones. We recently demonstrated that these drugs reverse insulin resistance through a previously unappreciated ..
  12. Pharmacogenomics of CVD risk Reduction
    ALAN SHULDINER; Fiscal Year: 2009
    ..Project 2: Pharmacogenomics of insulin sensitizing thiazolidinediones (TZDs) for CVD risk reduction: Insulin resistance is thought to play a causative role in the metabolic ..
  13. Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
    Talat Alp Ikizler; Fiscal Year: 2013
    ..mortality at one year of follow up among incident CHD patients with non-insulin requiring diabetes on thiazolidinediones (TZD)...
  14. PPAR gamma regulates vascular endothelial reactive species production in diabetes
    C Michael Hart; Fiscal Year: 2012
    ..The PI has demonstrated that direct activation of vascular endothelial cell PPARg with thiazolidinediones increased endothelial cell NO release and reduced superoxide production...
  15. An investigation of the mechanisms by which down-regulation of lipoprotein lipase
    Jheem D Medh; Fiscal Year: 2013
    ..In previous studies, it was demonstrated that chronic treatment of L6 rat myotubes with Thiazolidinediones (TZDs) drastically reduced their expression of LPL with a co-incident increase in glucose uptake...
  16. Effects of fish oil on inflammation and metabolic syndrome
    Philip A Kern; Fiscal Year: 2012
    ..Drugs such as thiazolidinediones (TZDs) improve insulin sensitivity via activation of PPAR-gamma, and there is much evidence that PPAR&#..
  17. Metabolic syndrome and hippocampal Ca2+ dysregulation in aging memory decline
    Olivier Thibault; Fiscal Year: 2013
    ..Moreover, the incidence of obesity and metabolic syndrome are approaching epidemic proportions. The thiazolidinediones (TZD), selective peroxisome proliferator-activated receptor-gamma (PPAR3) agonists, improve several aspects ..
  18. Mechanisms of Brd2 immunoprotection from insulin resistance
    Gerald V Denis; Fiscal Year: 2011
    ..b>Thiazolidinediones are insulin-sensitizing drugs that act as agonists of PPAR-gamma...
  19. Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer
    Raphael A Nemenoff; Fiscal Year: 2013
    ..This receptor is the target of thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone...
  20. PPAR-gamma and Vascular Lesion Formation
    Yuqing Eugene Chen; Fiscal Year: 2013
    ..The insulin-sensitizing thiazolidinediones (TZDs) are synthetic ligands of PPAR-? and the first drugs used to treat insulin resistance in patients with ..
  21. Regulation of glucose homeostasis by prokineticin 2 signaling
    Qun Yong Zhou; Fiscal Year: 2012
    ..Existing pharmacological options of hyperglycemia control include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, insulin and incretin agents...
  22. Safety and Effectiveness Evaluations for Diabetes
    DONALD READ MILLER; Fiscal Year: 2013
    ..proposal, we begin with a focus on the relative short-term and long-term safety of metformin, sulfonylurea, thiazolidinediones, and newer agents as well as a preliminary effectiveness analysis...
  23. Adipocyte Mithochondrial Dysfunction in Insulin Resistance
    Christian Meyer; Fiscal Year: 2010
    ..adipocyte mitochondria in insulin resistance and reversal of most of these abnormalities by treatment with thiazolidinediones (TZD), but FFA flux has not been determined...
  24. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory G Schwartz; Fiscal Year: 2013
    ..Moreover, many patients with insulin resistance are treated with PPAR agonist drugs (fibrates, thiazolidinediones) despite little knowledge of their cardiac effects...
  25. Novel Energy Restriction-Mimetic Agents for Prostate Cancer Prevention
    Ching Shih Chen; Fiscal Year: 2013
    ..Our studies have identified thiazolidinediones (TZDs) as a novel class of ERMAs in that they elicited hallmark cellular responses characteristic of energy ..
  26. Role of SMRT and NCoR in adipocyte differentation and function
    Ronald N Cohen; Fiscal Year: 2012
    ..However, the relationship between adiposity and diabetes is complex;for example, thiazolidinediones increase fat mass, yet improve insulin sensitivity...
  27. Regulation of Prostate Cancer Growth by PPARg Ligands
    LAMONICA VANETTE STEWART; Fiscal Year: 2010
    The long-term goal of this project is to define how thiazolidinediones (TZDs) and other ligands for the peroxisome proliferator activated receptor gamma (PPARg) could be used clinically to treat patients with prostate cancer...
  28. PPAR gamma in pediatric sepsis and the inflammatory response in obesity
    JENNIFER MELISSA KAPLAN; Fiscal Year: 2013
    ..The proposed research is significant because it can lead to novel therapies for patients with sepsis, including the potential use of FDA-approved PPARg ligands, thiazolidinediones, which can augment the PPARg pathway.
  29. Mechanistic studies of a PPAR-g mutation that causes lipodystrophy &diabetes
    OLGA IGOR ASTAPOVA; Fiscal Year: 2013
    ..receptor gamma (PPARg) has been implicated in the insulin signaling pathway as the target of thiazolidinediones, drugs that have recently been employed in the management of insulin-resistant disorders for their insulin-..
  30. Adipocyte insulin signaling and circulating adiponectin levels
    ROCIO INES PEREIRA; Fiscal Year: 2010
    ..b>Thiazolidinediones (TZDs), an insulin sensitizing class of drugs, increase adiponectin levels independently of their actions on ..
  31. Autologus adipose tissue grafts to inhibit hemodialysis access stenosis
    CHRISTI MARIE TERRY; Fiscal Year: 2012
    ..This technique may also improve fistula usability and has broad applicability to other vascular pathologies. ..
  32. Acute pancreatitis and obesity
    Giamila Fantuzzi; Fiscal Year: 2013
    ..The effect of metformin or thiazolidinediones- two drugs commonly used in insulin-resistant patients - on AP severity as well as production of cytokines ..
  33. Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation
    Li Qiang; Fiscal Year: 2013
    ..Obesity leads to insulin resistance and further Type 2 diabetes. Currently available insulin sensitizer thiazolidinediones (TZDs) are at skepticism for their detrimental effects...
  34. ABCs of Cholesterol Regulation in the Insulin Secretory Pathway
    JOHN DAVID CASTLE; Fiscal Year: 2013
    ..is reduced in models of type 2 diabetes and also figures in glucose sensitivity in response to anti-diabetic thiazolidinediones. Detailed analysis of ABCG1 in islet cells and islet-derived cell lines has shown unexpectedly that this ..
  35. An integrative approach to construct a regulatory network effected by TDZs
    Kyoung Jae Won; Fiscal Year: 2013
    ..b>Thiazolidinediones (TZDs) have a function to convert WAT into a "brownlike" state...
  36. PPAR-gamma ligands in colorectal cancer
    Seung Joon Baek; Fiscal Year: 2010
    ..PPARgamma ligands include prostaglandins of the J series, the synthetic antidiabetic thiazolidinediones, and oxidative metabolites of polyunsaturated fatty acids...
  37. Optimizing Recovery and Preservation of Endogenous Insulin Secretion
    STEVEN EMANUEL KAHN; Fiscal Year: 2013
    ..Attempts to prevent type 2 diabetes and its progression have shown that aside from intensive lifestyle, the thiazolidinediones (TZDs) are most effective...
  38. Neuroprotective Actions of Thiazolidinediones
    Sophia Sundararajan; Fiscal Year: 2009
    ..We describe exciting preliminary data we have obtained in a rat cerebral ischemia model suggesting that thiazolidinediones (TZDs), a class of drugs, already FDA approved for use in type 2 diabetes and currently under study as a ..
  39. Pharmacogenomics of Thiazolidinedione Response
    Soren Snitker; Fiscal Year: 2012
    b>Thiazolidinediones (TZDs) are a group of insulin-sensitizing drugs useful in the treatment and possibly in the prevention of type 2 diabetes mellitus...
  40. Fatty acid supplementation in management of type 2 diabetes
    Martha Belury; Fiscal Year: 2009
    ..The usage of insulin sensitizing drugs thiazolidinediones (TZDs) offers the hope of improving glycemic control while preserving beta cell function...
  41. Comparative Effectiveness of Anti-diabetic Medication Alternatives for Veterans
    Steven D Pizer; Fiscal Year: 2013
    ..Impacts on Veterans'Healthcare This study is designed to inform the VA formulary treatment of thiazolidinediones (TZDs) and insulin analogues, directly affecting VA patients'access and exposure to these medications...
  42. ABCs of Cholesterol Regulation in the Insulin Secretory Pathway
    JOHN DAVID CASTLE; Fiscal Year: 2011
    ..is reduced in models of type 2 diabetes and also figures in glucose sensitivity in response to anti-diabetic thiazolidinediones. Detailed analysis of ABCG1 in islet cells and islet-derived cell lines has shown unexpectedly that this ..
  43. Role of Vagal Afferents in Maintainence of Body Weight and Glucose Homeostasis
    Swalpa Udit; Fiscal Year: 2013
    ..chow feeding and in diet-induced obesity, if vagal afferents are required for the anti-diabetic actions of thiazolidinediones, and if vagal afferents are necessary for the anti-diabetic action of the CB1R antagonist class of drugs...
  44. The Role of PPARgamma in Lung Cancer Progression and Metastasis
    Howard Li; Fiscal Year: 2013
    ..accelerates metastasis, then there may be far-reaching implications for diabetics currently being prescribed thiazolidinediones. The Denver VA Medical Center and the Division of Pulmonary Sciences and Critical Care Medicine at the ..
  45. Gene Networks controlling macrophage-adipocyte interactions in insulin
    Christopher K Glass; Fiscal Year: 2013
    ..in vivo to determine mechanisms by which macrophage PPARy contributes to insulin-sensitizing functions of thiazolidinediones. We will investigate the roles o 3 dimensional chromatin interactions and non-coding RNAs in positive and ..
  46. Lipid Biology and Lipotoxicity
    Andrew D Robertson; Fiscal Year: 2011
    ..g., thiazolidinediones, metformin, or statins)...
  47. ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS
    Gary Gilkeson; Fiscal Year: 2005
    ..As agonists of PPAR gamma (the thiazolidinediones) are already approved for human use, insight gained from these studies can be quickly translated into human ..
  48. Interleukin-6 Expression and Function in Adipose Cells
    Jianbei Deng; Fiscal Year: 2006
    ..all on a C57BL/6J background at baseline and in response to glucocorticoid agonists and antagonists, and thiazolidinediones. Aim 3: To identify the differentiation-induced STAT3 activating ligand...
  49. The function(s) and regulation of PPARs in the ovary
    Carolyn Komar; Fiscal Year: 2003
    ..Because drugs that are known to activate PPARs, thiazolidinediones (a class of drugs used to treat hyperinsulinemia) and fibrates ( drugs used to treat hyperlipidemia) are ..
  50. PPAR- GAMMA LIGANDS IN ULCERATIVE COLITIS
    James Lewis; Fiscal Year: 2001
    ..A new class of diabetic drugs, the thiazolidinediones, has been developed to bind to the gamma subtype of the PPARs...
  51. Role of PPAR-gamma Isoforms in Regulation of Macrophage apoE & LPL Expression
    Jheem Medh; Fiscal Year: 2006
    ..protein isoform to bind to and be activated by various PPAR-g-specific ligands including eicosanoids and thiazolidinediones will be determined...
  52. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR EXPRESSION
    NICOLAS GUZMAN; Fiscal Year: 2001
    ..PPAR-gamma has been found to be the target of action of thiazolidinediones, a newly developed group of insulin-sensitizing antidiabetic agents used in the treatment of noninsulin- ..
  53. Association of PPAR gamma ligands & colonic neoplasia
    James Lewis; Fiscal Year: 2006
    ..A new class of diabetic drugs, the thiazolidinediones (TZDs), binds to the, /subtype of the PPARs...
  54. Protease Inhibitor Related Adipogenesis in HIV Infection
    Krishna Agrawal; Fiscal Year: 2003
    ..We will investigate the efficacy of thiazolidinediones (rosiglitazone and pioglitazone) and biguanides (metformin) in suppressing the effects of PI-induced ..
  55. Endogenous Mechanisms of PPAR Modulation
    Jorge Plutzky; Fiscal Year: 2005
    ..PPARy, activated by insulin-sensitizing thiazolidinediones, controls adipogenesis and glucose homeostasis...
  56. The impact of PPAR-gamma and estrogen receptor crosstalk on insulin action
    Andrea Hevener; Fiscal Year: 2007
    ..Similar to the effects of estrogen, PPAR-gamma (g) activation by thiazolidinediones (TZDs) causes insulin sensitization via alterations is transcription of genes involved in glucose and fatty ..
  57. Adipose Tissue-specific Angiogenesis and Insulin Sensitivity
    Silvia Corvera; Fiscal Year: 2009
    ..of adequate adipose cell capacity for lipid retention accounts for the apparently paradoxical finding that thiazolidinediones such as rosiglitazone, that cause net weight gain by stimulating the biogenesis of new adipose cells, ..
  58. Randomized Trial of Rosiglitazone for Ulcerative Colitis
    James Lewis; Fiscal Year: 2005
    ..A new class of diabetic drugs, the thiazolidinediones, has been developed to bind to the gamma (g) subtype of the PPARs...
  59. PHARMACOGENETICS OF PRO12ALA PPAR GAMMA 2 IN DIABETES
    ALAN SHULDINER; Fiscal Year: 2002
    ..from Applicant's Abstract): Clinical studies indicate that there is great variability in the ability of thiazolidinediones, a class of insulin-sensitizing agents, to improve glycemic control in patients with type 2 diabetes...
  60. MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS
    Steven Grinspoon; Fiscal Year: 2004
    ..differentiation, insulin sensitivity and expression of PPAR and other adipocyte regulatory genes using thiazolidinediones to determine whether PPAR gamma activation can rescue the differentiated phenotype...
  61. Rexinoid-Regulated Muscle Gene Expression
    Peter Davies; Fiscal Year: 2004
    ..There are two classes of nuclear receptor ligands, Retinoid X Receptor ligands (rexinoids) and PPARg ligands (thiazolidinediones-TZDs) that are capable of inducing insulin sensitization in animal models of Type II Diabetes...
  62. INHIBITION OF TRANSLATION INITIATION IN CANCER THERAPY
    Jose Halperin; Fiscal Year: 2005
    ..includes clotrimazole and non-imidazolic triphenyl derivatives, the n-3 unsaturated fatty acid EPA and the thiazolidinediones, which have potent anti-cancer activity in vitro and in animal models, downregulate translation initiation ..
  63. EFFECT OF FAT DEPOT ORIGIN ON PREADIPOCYTE FUNCTION
    James Kirkland; Fiscal Year: 2004
    ..PPARgamma is expressed after C/EBPbeta and promotes C/EBPalpha expression. Thiazolidinediones, which act by binding to PPARgamma are less effective in inducing epididymal than perirenal preadipocyte ..
  64. New Topical Therapies for Psoriasis
    Mitchell Avery; Fiscal Year: 2007
    ..In the current studies, we are investigating the antipsoriatic potential of topically administered thiazolidinediones, a novel class of drugs that has been shown to inhibit the proliferation of a variety of cell types ..
  65. New Topical Therapies for Psoriasis
    Harrihar Pershadsingh; Fiscal Year: 2004
    ..In the current studies, we will investigate the antipsoriatic potential of topically administered thiazolidinediones, a novel class of drugs, which have been shown to inhibit the proliferation of a variety of cell types ..
  66. The effects of allelic variation in Pparg on skeletal metabolism
    Cheryl Ackert Bicknell; Fiscal Year: 2007
    ..Approximately 21 % of Americans over the age of 60 currently have diabetes. Thiazolidinediones (TZDs) are popular drugs for the treatment of Type II diabetes, are ligands for PPARG, and have been shown ..
  67. Role of Perinatal Nutrition in the Development of Insulin Resistance
    Colleen Croniger; Fiscal Year: 2009
    ..2) investigate the in vivo functions of the PEPCK-C gene in the mammary gland and 3) determine the action of thiazolidinediones (TZD) in the alteration of the triglyceride/fatty acid cycle in the liver, adipose and mammary gland through ..
  68. MITOCHONDRIAL OXIDATIVE ENZYME EXPRESSION
    Tod Gulick; Fiscal Year: 2000
    ..including medium- or long-chain fatty acids, pharmacological manipulators of mitochondrial Beta-oxidation, thiazolidinediones, fibrates; or with insulin, glucagon, glucocorticoids, thyroid hormone, or retinoic acid in order to assess ..